Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2023-11-16 00:00:00 ET · period of report 2023-11-14 · accession 0000905148-23-001472 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-16 | 2023-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $5.08 | -239.0K | 2.66M | -8% | -$1.21M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-14 | F | D | 239,023 | $5.08 | 2,658,673 | D | — | — |